Drug Profile


Alternative Names: Eglumegad; LY-354740

Latest Information Update: 29 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Anxiolytics; Neuroprotectants; Small molecules; Smoking cessation therapies
  • Mechanism of Action Glutamate agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Neurological disorders; Panic disorder; Psychotic disorders; Schizophrenia; Seizures; Smoking withdrawal

Most Recent Events

  • 01 Aug 2006 No development reported - Phase-II for Panic disorder in USA (unspecified route)
  • 08 Oct 2003 A study has been added to the Anxiety disorders therapeutic trials section
  • 10 Jun 2003 A preclinical study has been added to the Psychotic disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top